Entecavir vs. Lamivudine in Preventing Hepatitis B Reactivation in Untreated DLBCL

feeds has 409 videos Subscribe Here

Description: In this video Dr. Jia Ruan explained the results from a randomized phase 3 trial published in JAMA (The Journal of the American Medical Association). In this study researchers compared the effectiveness of Entecavir and lamivudine in preventing HBV reactivation and clinically significant hepatitis in patients with DLBCL, who are receiving R-CHOP.Reactivation of the Hepatitis B virus (HBV) can be a serious and life threatening complication for lymphoma patients who receive Hepatitis B based treatment like R-CHOP.
Shared By : feeds
Posted on : 06/30/15
Added : 4 years ago
Category : Lymphoma